Skip to main content
Top
Published in: Digestive Diseases and Sciences 10/2015

01-10-2015 | Original Article

Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis

Authors: Ratnakar Shukla, Ujjala Ghoshal, Tapan N. Dhole, Uday C. Ghoshal

Published in: Digestive Diseases and Sciences | Issue 10/2015

Login to get access

Abstract

Background

Dysbiosis may play a role in irritable bowel syndrome (IBS), hitherto an enigmatic disorder. We evaluated selected fecal microbes in IBS patients and healthy controls (HC).

Methods

Fecal 16S rRNA copy number of selected bacteria was studied using qPCR in 47 patients with IBS (Rome III) and 30 HC.

Results

Of 47 patients, 20 had constipation (IBS-C), 20 diarrhea (IBS-D), and seven unclassified IBS (IBS-U). Relative difference in 16S rRNA copy number of Bifidobacterium (P = 0.042) was lower, while those of Ruminococcus productus-Clostridium coccoides (P = 0.016), Veillonella (P = 0.008), Bacteroides thetaiotamicron (P < 0.001), Pseudomonas aeruginosa (P < 0.001), and Gram-negative bacteria (GNB, P = 0.001) were higher among IBS patients than HC. Number of Lactobacillus (P = 0.002) was lower, while that of Bacteroides thetaiotamicron (P < 0.001) and segmented filamentous bacteria (SFB, P < 0.001) was higher among IBS-D than IBS-C. Numbers of Bacteroides thetaiotamicron (P < 0.001), P. aeruginosa (P < 0.001), and GNB (P < 0.01) were higher among IBS-C and IBS-D than HC. Quantity of SFB was higher among IBS-D (P = 0.011) and lower among IBS-C (P = 0.002) than HC. Number of Veillonella species was higher among IBS-C than HC (P = 0.002). P. aeruginosa was frequently detected among IBS than HC (46/47 [97.9 %] vs. 10/30 [33.3 %], P < 0.001). Abdominal distension (n = 34/47) was associated with higher number of Bacteroides thetaiotamicron, Clostridium coccoides, P. aeruginosa, SFB, and GNB; bloating (n = 22/47) was associated with Clostridium coccoides and GNB. Microbial flora was different among IBS than HC on principal component analysis.

Conclusion

Fecal microbiota was different among IBS than HC, and different sub-types were associated with different microbiota. P. aeruginosa was more frequent and higher in number among IBS patients.
Literature
1.
go back to reference Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130:1480–1491.CrossRefPubMed Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130:1480–1491.CrossRefPubMed
2.
go back to reference Malinen E, Krogius-Kurikka L, Lyra A, et al. Association of symptoms with gastrointestinal microbiota in irritable bowel syndrome. World J Gastroenterol. 2010;16:4532–4540.PubMedCentralCrossRefPubMed Malinen E, Krogius-Kurikka L, Lyra A, et al. Association of symptoms with gastrointestinal microbiota in irritable bowel syndrome. World J Gastroenterol. 2010;16:4532–4540.PubMedCentralCrossRefPubMed
3.
go back to reference Parkes GC, Brostoff J, Whelan K, Sanderson JD. Gastrointestinal microbiota in irritable bowel syndrome: their role in its pathogenesis and treatment. Am J Gastroenterol. 2008;103:1557–1567.CrossRefPubMed Parkes GC, Brostoff J, Whelan K, Sanderson JD. Gastrointestinal microbiota in irritable bowel syndrome: their role in its pathogenesis and treatment. Am J Gastroenterol. 2008;103:1557–1567.CrossRefPubMed
4.
go back to reference Ohman L, Simren M. New insights into the pathogenesis and pathophysiology of irritable bowel syndrome. Dig Liver Dis. 2007;39:201–215.CrossRefPubMed Ohman L, Simren M. New insights into the pathogenesis and pathophysiology of irritable bowel syndrome. Dig Liver Dis. 2007;39:201–215.CrossRefPubMed
5.
go back to reference Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364:22–32.CrossRefPubMed Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364:22–32.CrossRefPubMed
6.
go back to reference Guandalini S, Magazzu G, Chiaro A, et al. Vsl#3 improves symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo-controlled, double-blind, crossover study. J Pediatr Gastroenterol Nutr. 2010;51:24–30.CrossRefPubMed Guandalini S, Magazzu G, Chiaro A, et al. Vsl#3 improves symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo-controlled, double-blind, crossover study. J Pediatr Gastroenterol Nutr. 2010;51:24–30.CrossRefPubMed
7.
go back to reference Silk DB, Davis A, Vulevic J, Tzortzis G, Gibson GR. Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther. 2009;29:508–518.CrossRefPubMed Silk DB, Davis A, Vulevic J, Tzortzis G, Gibson GR. Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther. 2009;29:508–518.CrossRefPubMed
8.
go back to reference Malinen E, Rinttila T, Kajander K, et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time pcr. Am J Gastroenterol. 2005;100:373–382.CrossRefPubMed Malinen E, Rinttila T, Kajander K, et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time pcr. Am J Gastroenterol. 2005;100:373–382.CrossRefPubMed
10.
go back to reference Kerckhoffs AP, Ben-Amor K, Samsom M, et al. Molecular analysis of faecal and duodenal samples reveals significantly higher prevalence and numbers of pseudomonas aeruginosa in irritable bowel syndrome. J Med Microbiol. 2011;60:236–245.CrossRefPubMed Kerckhoffs AP, Ben-Amor K, Samsom M, et al. Molecular analysis of faecal and duodenal samples reveals significantly higher prevalence and numbers of pseudomonas aeruginosa in irritable bowel syndrome. J Med Microbiol. 2011;60:236–245.CrossRefPubMed
11.
go back to reference Sung J, Morales W, Kim G, et al. Effect of repeated campylobacter jejuni infection on gut flora and mucosal defense in a rat model of post infectious functional and microbial bowel changes. Neurogastroenterol Motil. 2013;25:529–537.CrossRefPubMed Sung J, Morales W, Kim G, et al. Effect of repeated campylobacter jejuni infection on gut flora and mucosal defense in a rat model of post infectious functional and microbial bowel changes. Neurogastroenterol Motil. 2013;25:529–537.CrossRefPubMed
12.
go back to reference Balsari A, Ceccarelli A, Dubini F, Fesce E, Poli G. The fecal microbial population in the irritable bowel syndrome. Microbiologica. 1982;5:185–194.PubMed Balsari A, Ceccarelli A, Dubini F, Fesce E, Poli G. The fecal microbial population in the irritable bowel syndrome. Microbiologica. 1982;5:185–194.PubMed
13.
go back to reference Liebregts T, Adam B, Bredack C, et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology. 2007;132:913–920.CrossRefPubMed Liebregts T, Adam B, Bredack C, et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology. 2007;132:913–920.CrossRefPubMed
16.
go back to reference Bellavia M, Damiano G, Gioviale MC, et al. Abnormal expansion of segmented filamentous bacteria in the gut: a role in pathogenesis of chronic inflammatory intestinal diseases? Rev Med Microbiol. 2011;22:45–47.CrossRef Bellavia M, Damiano G, Gioviale MC, et al. Abnormal expansion of segmented filamentous bacteria in the gut: a role in pathogenesis of chronic inflammatory intestinal diseases? Rev Med Microbiol. 2011;22:45–47.CrossRef
17.
go back to reference Hattori T, Fukudo S. Use of Rome III criteria for diagnosing irritable bowel syndrome. Nihon Rinsho. 2006;64:1425–1428.PubMed Hattori T, Fukudo S. Use of Rome III criteria for diagnosing irritable bowel syndrome. Nihon Rinsho. 2006;64:1425–1428.PubMed
18.
go back to reference Ghoshal UC, Gwee KA, Chen M, et al. Development, translation and validation of enhanced asian rome iii questionnaires for diagnosis of functional bowel diseases in major asian languages: a Rome foundation-asian neurogastroenterology and motility association working team report. J Neurogastroenterol Motil. 2015;21:83–92.PubMedCentralCrossRefPubMed Ghoshal UC, Gwee KA, Chen M, et al. Development, translation and validation of enhanced asian rome iii questionnaires for diagnosis of functional bowel diseases in major asian languages: a Rome foundation-asian neurogastroenterology and motility association working team report. J Neurogastroenterol Motil. 2015;21:83–92.PubMedCentralCrossRefPubMed
19.
go back to reference Bartosch S, Fite A, Macfarlane GT, McMurdo ME. Characterization of bacterial communities in feces from healthy elderly volunteers and hospitalized elderly patients by using real-time pcr and effects of antibiotic treatment on the fecal microbiota. Appl Environ Microbiol. 2004;70:3575–3581.PubMedCentralCrossRefPubMed Bartosch S, Fite A, Macfarlane GT, McMurdo ME. Characterization of bacterial communities in feces from healthy elderly volunteers and hospitalized elderly patients by using real-time pcr and effects of antibiotic treatment on the fecal microbiota. Appl Environ Microbiol. 2004;70:3575–3581.PubMedCentralCrossRefPubMed
20.
go back to reference Carroll IM, Chang YH, Park J, Sartor RB, Ringel Y. Luminal and mucosal-associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Gut Pathog. 2010;2:19.PubMedCentralCrossRefPubMed Carroll IM, Chang YH, Park J, Sartor RB, Ringel Y. Luminal and mucosal-associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Gut Pathog. 2010;2:19.PubMedCentralCrossRefPubMed
21.
go back to reference Matsuki T, Watanabe K, Tanaka R, Fukuda M, Oyaizu H. Distribution of bifidobacterial species in human intestinal microflora examined with 16s rRNA-gene-targeted species-specific primers. Appl Environ Microbiol. 1999;65:4506–4512.PubMedCentralPubMed Matsuki T, Watanabe K, Tanaka R, Fukuda M, Oyaizu H. Distribution of bifidobacterial species in human intestinal microflora examined with 16s rRNA-gene-targeted species-specific primers. Appl Environ Microbiol. 1999;65:4506–4512.PubMedCentralPubMed
22.
go back to reference Ponnusamy K, Choi JN, Kim J, Lee SY, Lee CH. Microbial community and metabolomic comparison of irritable bowel syndrome faeces. J Med Microbiol. 2011;60:817–827.PubMedCentralCrossRefPubMed Ponnusamy K, Choi JN, Kim J, Lee SY, Lee CH. Microbial community and metabolomic comparison of irritable bowel syndrome faeces. J Med Microbiol. 2011;60:817–827.PubMedCentralCrossRefPubMed
23.
go back to reference Qin X, Emerson J, Stapp J, Stapp L, Abe P, Burns JL. Use of real-time PCR with multiple targets to identify pseudomonas aeruginosa and other nonfermenting gram-negative bacilli from patients with cystic fibrosis. J Clin Microbiol. 2003;41:4312–4317.PubMedCentralCrossRefPubMed Qin X, Emerson J, Stapp J, Stapp L, Abe P, Burns JL. Use of real-time PCR with multiple targets to identify pseudomonas aeruginosa and other nonfermenting gram-negative bacilli from patients with cystic fibrosis. J Clin Microbiol. 2003;41:4312–4317.PubMedCentralCrossRefPubMed
24.
go back to reference Kubota H, Tsuji H, Matsuda K, Kurakawa T, Asahara T, Nomoto K. Detection of human intestinal catalase-negative, gram-positive cocci by rrna-targeted reverse transcription-PCR. Appl Environ Microbiol. 2010;76:5440–5451.PubMedCentralCrossRefPubMed Kubota H, Tsuji H, Matsuda K, Kurakawa T, Asahara T, Nomoto K. Detection of human intestinal catalase-negative, gram-positive cocci by rrna-targeted reverse transcription-PCR. Appl Environ Microbiol. 2010;76:5440–5451.PubMedCentralCrossRefPubMed
25.
go back to reference Conte MP, Schippa S, Zamboni I, et al. Gut-associated bacterial microbiota in paediatric patients with inflammatory bowel disease. Gut. 2006;55:1760–1767.PubMedCentralCrossRefPubMed Conte MP, Schippa S, Zamboni I, et al. Gut-associated bacterial microbiota in paediatric patients with inflammatory bowel disease. Gut. 2006;55:1760–1767.PubMedCentralCrossRefPubMed
26.
go back to reference Klausegger A, Hell M, Berger A, et al. Gram type-specific broad-range pcr amplification for rapid detection of 62 pathogenic bacteria. J Clin Microbiol. 1999;37:464–466.PubMedCentralPubMed Klausegger A, Hell M, Berger A, et al. Gram type-specific broad-range pcr amplification for rapid detection of 62 pathogenic bacteria. J Clin Microbiol. 1999;37:464–466.PubMedCentralPubMed
27.
28.
go back to reference Lyra A, Rinttila T, Nikkila J, et al. Diarrhoea-predominant irritable bowel syndrome distinguishable by 16s rRNA gene phylotype quantification. World J Gastroenterol. 2009;15:5936–5945.PubMedCentralCrossRefPubMed Lyra A, Rinttila T, Nikkila J, et al. Diarrhoea-predominant irritable bowel syndrome distinguishable by 16s rRNA gene phylotype quantification. World J Gastroenterol. 2009;15:5936–5945.PubMedCentralCrossRefPubMed
29.
go back to reference Kassinen A, Krogius-Kurikka L, Makivuokko H, et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology. 2007;133:24–33.CrossRefPubMed Kassinen A, Krogius-Kurikka L, Makivuokko H, et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology. 2007;133:24–33.CrossRefPubMed
30.
go back to reference Parkes GC, Rayment NB, Hudspith BN, et al. Distinct microbial populations exist in the mucosa-associated microbiota of sub-groups of irritable bowel syndrome. Neurogastroenterol Motil. 2011;24:31–39.CrossRefPubMed Parkes GC, Rayment NB, Hudspith BN, et al. Distinct microbial populations exist in the mucosa-associated microbiota of sub-groups of irritable bowel syndrome. Neurogastroenterol Motil. 2011;24:31–39.CrossRefPubMed
31.
go back to reference Yoon JS, Sohn W, Lee OY, et al. Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Gastroenterol Hepatol. 2014;29:52–59.CrossRefPubMed Yoon JS, Sohn W, Lee OY, et al. Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Gastroenterol Hepatol. 2014;29:52–59.CrossRefPubMed
32.
go back to reference Kerckhoffs AP, Samsom M, van der Rest ME, et al. Lower bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. World J Gastroenterol. 2009;15:2887–2892.PubMedCentralCrossRefPubMed Kerckhoffs AP, Samsom M, van der Rest ME, et al. Lower bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. World J Gastroenterol. 2009;15:2887–2892.PubMedCentralCrossRefPubMed
33.
go back to reference Spiller R. Review article: probiotics and prebiotics in irritable bowel syndrome. Aliment Pharmacol Ther. 2008;28:385–396.CrossRefPubMed Spiller R. Review article: probiotics and prebiotics in irritable bowel syndrome. Aliment Pharmacol Ther. 2008;28:385–396.CrossRefPubMed
34.
go back to reference Jeffery IB, Quigley EM, Ohman L, Simren M, O’Toole PW. The microbiota link to irritable bowel syndrome: an emerging story. Gut Microbes. 2012;3:572–576.PubMedCentralCrossRefPubMed Jeffery IB, Quigley EM, Ohman L, Simren M, O’Toole PW. The microbiota link to irritable bowel syndrome: an emerging story. Gut Microbes. 2012;3:572–576.PubMedCentralCrossRefPubMed
35.
go back to reference Ghoshal UC, Shukla R, Ghoshal U, Gwee KA, Ng SC, Quigley EMM. The gut microbiota and irritable bowel syndrome: friend or foe? Int J Inflamm. 2012. Ghoshal UC, Shukla R, Ghoshal U, Gwee KA, Ng SC, Quigley EMM. The gut microbiota and irritable bowel syndrome: friend or foe? Int J Inflamm. 2012.
36.
go back to reference Salonen A, de Vos WM, Palva A. Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives. Microbiology. 2010;156:3205–3215.CrossRefPubMed Salonen A, de Vos WM, Palva A. Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives. Microbiology. 2010;156:3205–3215.CrossRefPubMed
37.
go back to reference King TS, Elia M, Hunter JO. Abnormal colonic fermentation in irritable bowel syndrome. Lancet. 1998;352:1187–1189.CrossRefPubMed King TS, Elia M, Hunter JO. Abnormal colonic fermentation in irritable bowel syndrome. Lancet. 1998;352:1187–1189.CrossRefPubMed
39.
go back to reference Martens EC, Koropatkin NM, Smith TJ, Gordon JI. Complex glycan catabolism by the human gut microbiota: the bacteroidetes sus-like paradigm. J Biol Chem. 2009;284:24673–24677.PubMedCentralCrossRefPubMed Martens EC, Koropatkin NM, Smith TJ, Gordon JI. Complex glycan catabolism by the human gut microbiota: the bacteroidetes sus-like paradigm. J Biol Chem. 2009;284:24673–24677.PubMedCentralCrossRefPubMed
40.
go back to reference Rios-Covian D, Arboleya S, Hernandez-Barranco AM, et al. Interactions between bifidobacterium and bacteroides species in cofermentations are affected by carbon sources, including exopolysaccharides produced by bifidobacteria. Appl Environ Microbiol. 2013;79:7518–7524.PubMedCentralCrossRefPubMed Rios-Covian D, Arboleya S, Hernandez-Barranco AM, et al. Interactions between bifidobacterium and bacteroides species in cofermentations are affected by carbon sources, including exopolysaccharides produced by bifidobacteria. Appl Environ Microbiol. 2013;79:7518–7524.PubMedCentralCrossRefPubMed
41.
go back to reference Ng SC, Lam EF, Lam TT, et al. Effect of probiotic bacteria on the intestinal microbiota in irritable bowel syndrome. J Gastroenterol Hepatol. 2013;28:1624–1631.PubMed Ng SC, Lam EF, Lam TT, et al. Effect of probiotic bacteria on the intestinal microbiota in irritable bowel syndrome. J Gastroenterol Hepatol. 2013;28:1624–1631.PubMed
42.
go back to reference Tana C, Umesaki Y, Imaoka A, Handa T, Kanazawa M, Fukudo S. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil. 2010;22:512–519, e114–515. Tana C, Umesaki Y, Imaoka A, Handa T, Kanazawa M, Fukudo S. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil. 2010;22:512–519, e114–515.
43.
go back to reference Liu C, Finegold SM, Song Y, Lawson PA. Reclassification of clostridium coccoides, ruminococcus hansenii, ruminococcus hydrogenotrophicus, ruminococcus luti, ruminococcus productus and ruminococcus schinkii as blautia coccoides gen. Nov., comb. Nov., blautia hansenii comb. Nov., blautia hydrogenotrophica comb. Nov., blautia luti comb. Nov., blautia producta comb. Nov., blautia schinkii comb. Nov. And description of blautia wexlerae sp. Nov., isolated from human faeces. Int J Syst Evol Microbiol. 2008;58:1896–1902.CrossRefPubMed Liu C, Finegold SM, Song Y, Lawson PA. Reclassification of clostridium coccoides, ruminococcus hansenii, ruminococcus hydrogenotrophicus, ruminococcus luti, ruminococcus productus and ruminococcus schinkii as blautia coccoides gen. Nov., comb. Nov., blautia hansenii comb. Nov., blautia hydrogenotrophica comb. Nov., blautia luti comb. Nov., blautia producta comb. Nov., blautia schinkii comb. Nov. And description of blautia wexlerae sp. Nov., isolated from human faeces. Int J Syst Evol Microbiol. 2008;58:1896–1902.CrossRefPubMed
44.
go back to reference Treem WR, Ahsan N, Kastoff G, Hyams JS. Fecal short-chain fatty acids in patients with diarrhea-predominant irritable bowel syndrome: In vitro studies of carbohydrate fermentation. J Pediatr Gastroenterol Nutr. 1996;23:280–286.CrossRefPubMed Treem WR, Ahsan N, Kastoff G, Hyams JS. Fecal short-chain fatty acids in patients with diarrhea-predominant irritable bowel syndrome: In vitro studies of carbohydrate fermentation. J Pediatr Gastroenterol Nutr. 1996;23:280–286.CrossRefPubMed
45.
go back to reference Bourdu S, Dapoigny M, Chapuy E, et al. Rectal instillation of butyrate provides a novel clinically relevant model of noninflammatory colonic hypersensitivity in rats. Gastroenterology. 2005;128:1996–2008.CrossRefPubMed Bourdu S, Dapoigny M, Chapuy E, et al. Rectal instillation of butyrate provides a novel clinically relevant model of noninflammatory colonic hypersensitivity in rats. Gastroenterology. 2005;128:1996–2008.CrossRefPubMed
46.
go back to reference Chichlowski M, Hale LP. Bacterial-mucosal interactions in inflammatory bowel disease: an alliance gone bad. Am J Physiol Gastrointest Liver Physiol. 2008;295:G1139–G1149.PubMedCentralCrossRefPubMed Chichlowski M, Hale LP. Bacterial-mucosal interactions in inflammatory bowel disease: an alliance gone bad. Am J Physiol Gastrointest Liver Physiol. 2008;295:G1139–G1149.PubMedCentralCrossRefPubMed
47.
go back to reference Dulon S, Leduc D, Cottrell GS, et al. Pseudomonas aeruginosa elastase disables proteinase-activated receptor 2 in respiratory epithelial cells. Am J Respir Cell Mol Biol. 2005;32:411–419.CrossRefPubMed Dulon S, Leduc D, Cottrell GS, et al. Pseudomonas aeruginosa elastase disables proteinase-activated receptor 2 in respiratory epithelial cells. Am J Respir Cell Mol Biol. 2005;32:411–419.CrossRefPubMed
49.
go back to reference Srivastava D, Ghoshal U, Mittal RD, Ghoshal UC. Associations between IL-1RA polymorphisms and small intestinal bacterial overgrowth among patients with irritable bowel syndrome from India. Neurogastroenterol Motil. 2014;26:1408–1416.CrossRefPubMed Srivastava D, Ghoshal U, Mittal RD, Ghoshal UC. Associations between IL-1RA polymorphisms and small intestinal bacterial overgrowth among patients with irritable bowel syndrome from India. Neurogastroenterol Motil. 2014;26:1408–1416.CrossRefPubMed
50.
go back to reference Rodriguez-Fandino O, Hernandez-Ruiz J, Schmulson M. From cytokines to toll-like receptors and beyond—current knowledge and future research needs in irritable bowel syndrome. J Neurogastroenterol Motil. 2010;16:363–373.PubMedCentralCrossRefPubMed Rodriguez-Fandino O, Hernandez-Ruiz J, Schmulson M. From cytokines to toll-like receptors and beyond—current knowledge and future research needs in irritable bowel syndrome. J Neurogastroenterol Motil. 2010;16:363–373.PubMedCentralCrossRefPubMed
51.
Metadata
Title
Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis
Authors
Ratnakar Shukla
Ujjala Ghoshal
Tapan N. Dhole
Uday C. Ghoshal
Publication date
01-10-2015
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 10/2015
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-015-3607-y

Other articles of this Issue 10/2015

Digestive Diseases and Sciences 10/2015 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.